Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan
Publication
, Conference
Bristow, M; Eichhorn, E; Ventura, H; Koch, B; Fiuzat, M; Davis, G; Robertson, AD
Published in: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
March 10, 2009
Duke Scholars
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
March 10, 2009
Volume
53
Issue
10
Start / End Page
A157 / A157
Location
Orlando, FL
Publisher
ELSEVIER SCIENCE INC
Conference Name
58th Annual Scientific Session of the American-College-of-Cardiology
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Bristow, M., Eichhorn, E., Ventura, H., Koch, B., Fiuzat, M., Davis, G., & Robertson, A. D. (2009). Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 53, pp. A157–A157). Orlando, FL: ELSEVIER SCIENCE INC.
Bristow, Michael, Eric Eichhorn, Hector Ventura, Bruce Koch, Mona Fiuzat, Gordon Davis, and A Douglas Robertson. “Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan.” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 53:A157–A157. ELSEVIER SCIENCE INC, 2009.
Bristow M, Eichhorn E, Ventura H, Koch B, Fiuzat M, Davis G, et al. Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2009. p. A157–A157.
Bristow, Michael, et al. “Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 53, no. 10, ELSEVIER SCIENCE INC, 2009, pp. A157–A157.
Bristow M, Eichhorn E, Ventura H, Koch B, Fiuzat M, Davis G, Robertson AD. Beta-Blocker Evaluation of Survival Trial (BEST) Findings Show Benefit of Bucindolol in Moderate to Severe HF Patients, According to Prespecified Statistical Analysis Plan. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2009. p. A157–A157.
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
March 10, 2009
Volume
53
Issue
10
Start / End Page
A157 / A157
Location
Orlando, FL
Publisher
ELSEVIER SCIENCE INC
Conference Name
58th Annual Scientific Session of the American-College-of-Cardiology
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology